When Will Invivyd, Inc. (NASDAQ:IVVD) Breakeven?

Invivyd, Inc. (NASDAQ:IVVD) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The US$122m market-cap company posted a loss in its most recent financial year of US$199m and a latest trailing-twelve-month loss of US$204m leading to an even wider gap between loss and breakeven. As path to profitability is the topic on Invivyd's investors mind, we've decided to gauge market sentiment. Below we will provide a high-level summary of the industry analysts’ expectations for the company.

View our latest analysis for Invivyd

According to the 4 industry analysts covering Invivyd, the consensus is that breakeven is near. They expect the company to post a final loss in 2025, before turning a profit of US$62m in 2026. Therefore, the company is expected to breakeven roughly 2 years from now. How fast will the company have to grow each year in order to reach the breakeven point by 2026? Working backwards from analyst estimates, it turns out that they expect the company to grow 70% year-on-year, on average, which signals high confidence from analysts. Should the business grow at a slower rate, it will become profitable at a later date than expected.

Underlying developments driving Invivyd's growth isn’t the focus of this broad overview, however, take into account that generally biotechs, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.

One thing we’d like to point out is that Invivyd has no debt on its balance sheet, which is rare for a loss-making biotech, which typically has high debt relative to its equity. The company currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment.

Next Steps:

There are key fundamentals of Invivyd which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at Invivyd, take a look at Invivyd's company page on Simply Wall St. We've also compiled a list of pertinent aspects you should further research:

1. Valuation: What is Invivyd worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Invivyd is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Invivyd’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.